Alimera Sciences, Inc.
ALIM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.00 | 0.21 | 0.08 |
| FCF Yield | -81.31% | -53.95% | -11.36% | -13.02% |
| EV / EBITDA | -148.64 | -6.49 | 25.61 | 25.29 |
| Quality | ||||
| ROIC | -1.46% | -39.81% | -0.48% | -1.22% |
| Gross Margin | 75.75% | 85.26% | 88.09% | 86.34% |
| Cash Conversion Ratio | 0.71 | 0.55 | 0.74 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.01% | 2.12% | 3.05% | 2.66% |
| Free Cash Flow Growth | -777.74% | -166.06% | -36.69% | 34.97% |
| Safety | ||||
| Net Debt / EBITDA | -49.60 | -4.37 | 11.38 | 15.36 |
| Interest Coverage | -0.19 | -1.98 | -0.04 | -0.09 |
| Efficiency | ||||
| Inventory Turnover | 10.42 | 4.97 | 2.62 | 2.53 |
| Cash Conversion Cycle | 37.36 | -255.91 | -194.65 | -124.41 |